Patent EP4247855A1: Anti-CD73 Antibody, Drug Conjugate, and Use
Summary
The European Patent Office has published patent application EP4247855A1 concerning an anti-CD73 antibody, antibody-drug conjugate, and its therapeutic use. The patent was applied for by Bliss Biopharmaceutical (Hangzhou) Co., Ltd. and published on March 11, 2026.
What changed
This document is a publication of a European patent application (EP4247855A1) for an anti-CD73 antibody, antibody-drug conjugate, and its use, filed by Bliss Biopharmaceutical (Hangzhou) Co., Ltd. The publication date is March 11, 2026.
As this is a patent publication, it does not impose direct compliance obligations on regulated entities. However, it signifies potential new intellectual property in the field of oncology therapeutics, which may impact future drug development and market exclusivity for competitors. Legal and R&D departments should be aware of this filing for competitive intelligence purposes.
Source document (simplified)
ANTI-CD73 ANTIBODY, ANTIBODY-DRUG CONJUGATE, AND USE THEREOF
Publication EP4247855A1 Kind: A1 Mar 11, 2026
Applicants
Bliss Biopharmaceutical (Hangzhou) Co., Ltd.
Inventors
XIA, Bing, FENG, Cui, GU, Lixia, LI, Chen, ZHOU, Yuhong, WEI, Ziping
IPC Classifications
C07K 16/32 20060101AFI20241125BHEP C07K 16/28 20060101ALI20241125BHEP A61K 39/00 20060101ALI20241125BHEP A61P 35/00 20060101ALI20241125BHEP A61K 47/68 20170101ALI20241125BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Named provisions
Related changes
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get Pharma & Drug Safety alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Peptides (C07K) publishes new changes.